E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer

Chen,Heming; Chen,Weihong; Zhang,Xiaojun; Hu,Lin; Tang,Guojun; Kong,Juan; Wang,Zhiwei

doi:10.3892/or.2018.6807

E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer

Authors:
- Heming Chen
- Weihong Chen
- Xiaojun Zhang
- Lin Hu
- Guojun Tang
- Juan Kong
- Zhiwei Wang
View Affiliations

Affiliations: Department of Endocrinology, Ankang Central Hospital, Ankang, Shaanxi 725000, P.R. China, Department of Nephropathy, Ankang Central Hospital, Ankang, Shaanxi 725000, P.R. China, Department of General Practice, Zhoukou Central Hospital, Zhoukou, Henan 466000, P.R. China, Department of Gland Surgery, Ankang Central Hospital, Ankang, Shaanxi 725000, P.R. China
Published online on: October 18, 2018 https://doi.org/10.3892/or.2018.6807
Pages: 570-578

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thyroid cancer is the most commonly diagnosed malignancy of the endocrine system, the incidence of which has increased rapidly in the last 30 years. Genetic alterations in pathways, including the mitogen‑activated protein kinase (MAPK)/extracellular signal‑regulated kinase (Erk) and phosphatidylinositol‑3‑kinase (PI3K)/protein kinase B (Akt) pathways, are the driving force behind the development of differentiated thyroid cancer cases into aggressive and undifferentiated forms of thyroid cancer. E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) belong to the epithelial‑specific subfamily of ETS transcription factors and has recently been reported to be involved in various pathophysiological processes. However, the role of ELF3 in thyroid cancer has not yet been investigated. In the present study, data from The Cancer Genome Atlas (TCGA) were analyzed, and it was revealed that ELF3 was overexpressed in patients with papillary thyroid cancer (PTC). Furthermore, the expression of ELF3 was found to be higher in thyroid cancer tissues with a B‑Raf proto‑oncogene (BRAF) mutation as determined by western blot analysis and IHC staining. Additionally, ELF3 overexpression predicted a poor prognosis in patients with PTC. The MAPK signaling pathway inhibitor PLX4032 was demonstrated to strongly attenuate ELF3 protein levels in BRAF‑mutant thyroid cancer cell lines. Knockdown of ELF3 with small interfering RNA (siRNA) inhibited the growth, clone formation, migration and invasion of BRAF mutant thyroid cancer cells. Mechanistically, ELF3 modulated the activity of the MAPK/Erk pathway via transcriptional regulation of the human epidermal growth factor receptor 2 family of receptors as determined by RT‑qPCR. In conclusion, the present study demonstrated ELF3 to be a potential prognostic marker for patients with thyroid cancer. Notably, ELF3 was demonstrated to form a positive feedback loop with MAPK pathways leading to the progression of BRAF‑mutant thyroid cancer.

View Figures

View References

1	Chen AY, Jemal A and Ward EM: Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 115:3801–3807. 2009. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, et al: Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 26:879–885. 2002. View Article : Google Scholar : PubMed/NCBI
4	Burns WR and Zeiger MA: Differentiated thyroid cancer. Semin Oncol. 37:557–566. 2010. View Article : Google Scholar : PubMed/NCBI
5	Xing M: Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013. View Article : Google Scholar : PubMed/NCBI
6	Nikiforov YE and Nikiforova MN: Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 7:569–580. 2011. View Article : Google Scholar : PubMed/NCBI
7	Cancer Genome Atlas Research Network: Integrated genomic characterization of papillary thyroid carcinoma. Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
8	Oikawa T and Yamada T: Molecular biology of the Ets family of transcription factors. Gene. 303:11–34. 2003. View Article : Google Scholar : PubMed/NCBI
9	Oliver JR, Kushwah R and Hu J: Multiple roles of the epithelium-specific ETS transcription factor, ESE-1, in development and disease. Lab Invest. 92:320–330. 2012. View Article : Google Scholar : PubMed/NCBI
10	Longoni N, Sarti M, Albino D, Civenni G, Malek A, Ortelli E, Pinton S, Mello-Grand M, Ostano P, D'Ambrosio G, et al: ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression. Cancer Res. 73:4533–4547. 2013. View Article : Google Scholar : PubMed/NCBI
11	Gajulapalli VN, Samanthapudi VS, Pulaganti M, Khumukcham SS, Malisetty VL, Guruprasad L, Chitta SK and Manavathi B: A transcriptional repressive role for epithelial-specific ETS factor ELF3 on oestrogen receptor alpha in breast cancer cells. Biochem J. 473:1047–1061. 2016. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Cancer Genome Atlas Research Network. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome atlas pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013. View Article : Google Scholar : PubMed/NCBI
14	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
15	Haugen DR, Akslen LA, Varhaug JE and Lillehaug JR: Expression of c-erbB-2 protein in papillary thyroid carcinomas. Br J Cancer. 65:832–837. 1992. View Article : Google Scholar : PubMed/NCBI
16	Haugen DR, Akslen LA, Varhaug JE and Lillehaug JR: Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res. 56:1184–1188. 1996.PubMed/NCBI
17	Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S and Mitsiades N: Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: Mutational and functional analysis. J Clin Endocrinol Metab. 91:3662–3666. 2006. View Article : Google Scholar : PubMed/NCBI
18	Lemmon MA and Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010. View Article : Google Scholar : PubMed/NCBI
19	Wang JL, Chen ZF, Chen HM, Wang MY, Kong X, Wang YC, Sun TT, Hong J, Zou W, Xu J, et al: Elf3 drives β-catenin transactivation and associates with poor prognosis in colorectal cancer. Cell Death Dis. 5:e12632014. View Article : Google Scholar : PubMed/NCBI
20	Yeung TL, Leung CS, Wong KK, Gutierrez-Hartmann A, Kwong J, Gershenson DM and Mok SC: ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget. 8:16951–16963. 2017. View Article : Google Scholar : PubMed/NCBI
21	Gingras MC, Covington KR, Chang DK, Donehower LA, Gill AJ, Ittmann MM, Creighton CJ, Johns AL, Shinbrot E, Dewal N, et al: Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Rep. 14:907–919. 2016. View Article : Google Scholar : PubMed/NCBI
22	Yachida S, Wood LD, Suzuki M, Takai E, Totoki Y, Kato M, Luchini C, Arai Y, Nakamura H, Hama N, et al: Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma. Cancer Cell. 29:229–240. 2016. View Article : Google Scholar : PubMed/NCBI
23	de Nigris F, Mega T, Berger N, Barone MV, Santoro M, Viglietto G, Verde P and Fusco A: Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. Cancer Res. 61:2267–2275. 2001.PubMed/NCBI
24	Scott GK, Daniel JC, Xiong X, Maki RA, Kabat D and Benz CC: Binding of an ETS-related protein within the DNase I hypersensitive site of the HER2/neu promoter in human breast cancer cells. J Biol Chem. 269:19848–19858. 1994.PubMed/NCBI
25	Chang CH, Scott GK, Kuo WL, Xiong X, Suzdaltseva Y, Park JW, Sayre P, Erny K, Collins C, Gray JW, et al: ESX: A structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene. 14:1617–1622. 1997. View Article : Google Scholar : PubMed/NCBI
26	Eckel KL, Tentler JJ, Cappetta GJ, Diamond SE and Gutierrez-Hartmann A: The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression. DNA Cell Biol. 22:79–94. 2003. View Article : Google Scholar : PubMed/NCBI
27	Fisher KE, Jani JC, Fisher SB, Foulks C, Hill CE, Weber CJ, Cohen C and Sharma J: Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma. J Surg Res. 185:217–224. 2013. View Article : Google Scholar : PubMed/NCBI
28	Landriscina M, Pannone G, Piscazzi A, Toti P, Fabiano A, Tortorella S, Occhini R, Ambrosi A, Bufo P and Cignarelli M: Epidermal growth factor receptor 1 expression is upregulated in undifferentiated thyroid carcinomas in humans. Thyroid. 21:1227–1234. 2011. View Article : Google Scholar : PubMed/NCBI
29	Kolch W and Pitt A: Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer. 10:618–629. 2010. View Article : Google Scholar : PubMed/NCBI
30	Liu J, Cho SN, Akkanti B, Jin N, Mao J, Long W, Chen T, Zhang Y, Tang X, Wistub II, et al: ErbB2 pathway activation upon Smad4 loss promotes lung tumor growth and metastasis. Cell Rep. Mar 3–2015.(Epub ahead of print).